The clinical use of nuclear medicine imaging and therapy in pancreatic neuroendocrine tumors has been greatly strengthened since the approval of ^(68)Ga-DOTATATE and ^(177)Lu-DOTATATE.However,many aspects are still un...The clinical use of nuclear medicine imaging and therapy in pancreatic neuroendocrine tumors has been greatly strengthened since the approval of ^(68)Ga-DOTATATE and ^(177)Lu-DOTATATE.However,many aspects are still under discussion.In this 2-part article,we aim to collect and discuss current evidence of molecular imaging and peptide receptor radionuclide therapy(PRRT)in pancreatic neuroendocrine tumor.In the first part,we will address some critical aspects of ^(68)Ga-SSAs imaging,including diagnostic efficacy,recurrence detection and follow-up,patient selection for PRRT,and pitfalls in image interpretation.Besides,we will also briefly discuss the role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography,special imaging strategy in regard to insulinoma,and the status of radiolabeled somatostatin receptor antagonist.In the second part,we aim to review the current evidence of PRRT in pancreatic neuroendocrine tumor,focusing on efficacy and safety in particular.We will also introduce the recent development of PRRT,including PRRT in high-grade neuroendocrine neoplasms,retreatment PRRT,upfront PRRT,PRRT in the setting of neoadjuvant therapy and conversion therapy,combination therapies with PRRT,PRRT withαradionuclides,and PRRT with antagonists.展开更多
Cancer has remained one of the biggest challenges for human health during the past few decades despite major advances in medicine[1].Poor prognosis of cancer is mainly caused by a lack of effective treatment.Moreover,...Cancer has remained one of the biggest challenges for human health during the past few decades despite major advances in medicine[1].Poor prognosis of cancer is mainly caused by a lack of effective treatment.Moreover,many patients cannot receive appropriate treatment despite early diagnosis.High heterogeneity is a tumor characteristic and different types of cancer usually vary in clinical features and tumorigenic mechanisms,which results in different responses to drugs[2].How to predict accurately the patient’s response to drugs and choose personalized treatment is one of themain concerns of doctors.展开更多
Pancreatic cancer is one of the most lethal malignancies in the world.Cancer-associated fibroblasts are one of the main components of tumor microenvironment in pancreatic cancer and play an essential role in tumor pro...Pancreatic cancer is one of the most lethal malignancies in the world.Cancer-associated fibroblasts are one of the main components of tumor microenvironment in pancreatic cancer and play an essential role in tumor progression.Fibroblast activation protein that is expressed in specific subtypes of cancer-associated fibroblasts promotes tumor growth and is related to poor survival.Recent researches have preliminarily demonstrated a promising potential of radiopharmaceuticals targeting fibroblast activation protein in diagnosis and therapy of pancreatic cancer.This article comprehensively reviews the current development and clinical translation of fibroblast activation protein inhibitor-targeting radiopharmaceuticals in pancreatic cancer and provides significant perspectives for future investigations.展开更多
基金funded by CAMS Innovation Fund for Medical Sciences(CIFMS)(2022-I2M-JB-001)National High Level Hospital Clinical Research Funding(No.2022-PUMCH-B-072).
文摘The clinical use of nuclear medicine imaging and therapy in pancreatic neuroendocrine tumors has been greatly strengthened since the approval of ^(68)Ga-DOTATATE and ^(177)Lu-DOTATATE.However,many aspects are still under discussion.In this 2-part article,we aim to collect and discuss current evidence of molecular imaging and peptide receptor radionuclide therapy(PRRT)in pancreatic neuroendocrine tumor.In the first part,we will address some critical aspects of ^(68)Ga-SSAs imaging,including diagnostic efficacy,recurrence detection and follow-up,patient selection for PRRT,and pitfalls in image interpretation.Besides,we will also briefly discuss the role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography,special imaging strategy in regard to insulinoma,and the status of radiolabeled somatostatin receptor antagonist.In the second part,we aim to review the current evidence of PRRT in pancreatic neuroendocrine tumor,focusing on efficacy and safety in particular.We will also introduce the recent development of PRRT,including PRRT in high-grade neuroendocrine neoplasms,retreatment PRRT,upfront PRRT,PRRT in the setting of neoadjuvant therapy and conversion therapy,combination therapies with PRRT,PRRT withαradionuclides,and PRRT with antagonists.
基金supported by grants from the CAMS Innovation Fund for Medical Sciences(CIFMS)(No.2016-I2M-1–001)and the National High-tech Research and Development Projects(863)(No.2015AA020303).
文摘Cancer has remained one of the biggest challenges for human health during the past few decades despite major advances in medicine[1].Poor prognosis of cancer is mainly caused by a lack of effective treatment.Moreover,many patients cannot receive appropriate treatment despite early diagnosis.High heterogeneity is a tumor characteristic and different types of cancer usually vary in clinical features and tumorigenic mechanisms,which results in different responses to drugs[2].How to predict accurately the patient’s response to drugs and choose personalized treatment is one of themain concerns of doctors.
基金This work was in part supported by the National Natural Science Foundation of China(No.82071967)CAMS Innovation Fund for Medical Science(No.CIFMS-2021-I2M-1-025)+2 种基金National Key Research and Development Program of China(No.2016YFC0901500)CAMS Fund for Rare Diseases Research(No.2016ZX310174-4)Tsinghua university and PUMCH Joint Fund(No.PTQH201906006).
文摘Pancreatic cancer is one of the most lethal malignancies in the world.Cancer-associated fibroblasts are one of the main components of tumor microenvironment in pancreatic cancer and play an essential role in tumor progression.Fibroblast activation protein that is expressed in specific subtypes of cancer-associated fibroblasts promotes tumor growth and is related to poor survival.Recent researches have preliminarily demonstrated a promising potential of radiopharmaceuticals targeting fibroblast activation protein in diagnosis and therapy of pancreatic cancer.This article comprehensively reviews the current development and clinical translation of fibroblast activation protein inhibitor-targeting radiopharmaceuticals in pancreatic cancer and provides significant perspectives for future investigations.
